Журнал кардиореспираторных исследований 2025. №2/2
Maqola mavzusi
PODAGRA RIVOJLANISHINING XAVF OMILLARI VA KLINIK XUSUSIYATLARI (95-102)
Mualliflar
Pulatov Ulug‘bek Sunatovich, Shodiqulova Gulandon Zikiryaevna, Karimov Azizjon Xamraqulovich
Muassasa
Samarqand Davlat Tibbiyot universiteti
Annotatsiya
Ushbu tahliliy maqola siydik kislotasi darajasining oshishi natijasida yuzaga keladigan metabolik kasallik bo'lgan podagraning xavf omillari va klinik xususiyatlariga qaratilgan. Maqolada podagra rivojlanishiga hissa qo'shadigan genetik moyillik va ekzogen omillar, shu jumladan noto'g'ri ovqatlanish, harakatsiz turmush tarzi va birga keladigan patologiyalar tahlil qilinadi. Zamonaviy diagnostika usullari, shuningdek, takroriy hujumlar xavfini sezilarli darajada kamaytiradigan farmakologik terapiya va turmush tarzini o'zgartirishni o'z ichiga olgan davolash usullari muhokama qilinadi.
Kalit so'zlar
Podagra, xavf omillari, klinik xususiyatlari, siydik kislotasi, davolash.
Adabiyotlar
1. Abhishek A, Valdes AM, Jenkins W, Zhang W, Doherty M. Triggers of acute attacks of gout, does age of gout onset matter? A primary care based cross-sectional study. PLoS One. 2017 Oct 12;12(10):e0186096. doi: 10.1371/journal.pone.0186096. PMID: 29023487; PMCID: PMC5638318. 2. Amatucci AJ, Padnick-Silver L, LaMoreaux B, Bulbin DH. Comparison Between Early-Onset and Common Gout: A Systematic Literature Review. Rheumatol Ther. 2023 Aug;10(4):809-823. doi: 10.1007/s40744-023-00565-x. Epub 2023 Jun 19. PMID: 37335432; PMCID: PMC10326179. 3. Bowden RG, Richardson KA, Richardson LT. Uric acid and metabolic syndrome: Findings from national health and nutrition examination survey. Front Med (Lausanne). 2022 Dec 14;9:1039230. doi: 10.3389/fmed.2022.1039230. PMID: 36590930; PMCID: PMC9795410. 4. Cai N, Chen M, Feng P, Zheng Q, Zhu X, Yang S, Zhang Z, Wang Y. Relationships between obesity and prevalence of gout in patients with type 2 diabetes mellitus: a cross-sectional population-based study. BMC Endocr Disord. 2024 Aug 2;24(1):137. doi: 10.1186/s12902-024-01672-8. PMID: 39090627; PMCID: PMC11295670. 5. Cai N, Chen M, Wu L, Feng P, Ye X, Liu Q, Zhu X, Lu C, Zheng Q, Wang Y. Association between physical activity and the prevalence of gout among patients with type 2 diabetes mellitus and hyperuricemia: a two-center population- based cross-sectional study. Clin Rheumatol. 2024 Sep;43(9):2955-2961. doi: 10.1007/s10067-024-07081-5. Epub 2024 Jul 26. PMID: 39060811; PMCID: PMC11330382. 6. Cao L, Zhao T, Xie C, Zheng S, Wan W, Zou H, Zhu X. Performance of Ultrasound in the Clinical Evaluation of Gout and Hyperuricemia. J Immunol Res. 2021 Apr 5;2021:5550626. doi: 10.1155/2021/5550626. PMID: 33884273; PMCID: PMC8041551 7. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016 Oct 22;388(10055):2039-2052. doi: 10.1016/S0140- 6736(16)00346-9. Epub 2016 Apr 21. PMID: 27112094. 8. Dehlin, M., Jacobsson, L. & Roddy, E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol 16, 380–390 (2020). https://doi.org/10.1038/s41584-020-0441-1 9. Dirken-Heukensfeldt KJ, Teunissen TA, van de Lisdonk H, Lagro-Janssen AL. "Clinical features of women with gout arthritis." A systematic review. Clin Rheumatol. 2010 Jun;29(6):575-82. doi: 10.1007/s10067-009-1362-1. Epub 2010 Jan 19. PMID: 20084441; PMCID: PMC2860089. 10. Du XL, Liu L, Song W, Zhou X, Lv ZT. Association between Gout and Erectile Dysfunction: A Systematic Review and Meta-Analysis. PLoS One. 2016 Dec 30;11(12):e0168784. doi: 10.1371/journal.pone.0168784. PMID: 28036397; PMCID: PMC5201298. 11. Ebstein E, Ottaviani S. Managing Gout in Patients with Metabolic Syndrome. Drugs Aging. 2024 Aug;41(8):653- 663. doi: 10.1007/s40266-024-01132-x. Epub 2024 Jul 27. PMID: 39060816. 12. Fenando A, Rednam M, Gujarathi R, et al. Gout. [Updated 2024 Feb 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK546606/ 13. Guan Y, Wei J, Meng L, Li Y, Wang T, Chen D, Qian Q. Genetically predicted physical activity is associated with lower serum urate concentrations. Genes Genomics. 2022 Jul;44(7):843-853. doi: 10.1007/s13258-022-01239-8. Epub 2022 May 27. PMID: 35622233. 14. Ha YJ, Chung SW, Lee JH, Kang EH, Lee YJ, Song YW. Clinical features and risk factors for gout attacks during anti-tuberculosis treatment: A case-control study in South Korea. Int J Rheum Dis. 2019 Oct;22(10):1905-1911. doi: 10.1111/1756-185X.13697. Epub 2019 Sep 17. PMID: 31531949. 15. Han T, Chen W, Qiu X, Wang W. Epidemiology of gout - Global burden of disease research from 1990 to 2019 and future trend predictions. Ther Adv Endocrinol Metab. 2024 Mar 4;15:20420188241227295. doi: 10.1177/20420188241227295. PMID: 38439915; PMCID: PMC10910883. 16. Helget LN, Mikuls TR. Environmental Triggers of Hyperuricemia and Gout. Rheum Dis Clin North Am. 2022 Nov;48(4):891-906. doi: 10.1016/j.rdc.2022.06.009. PMID: 36333002; PMCID: PMC10351897. 17. Jasvinder A. Singh, Angelo Gaffo. Gout epidemiology and comorbidities, Seminars in Arthritis and Rheumatism, Volume 50, Issue 3, Supplement, 2020, P.11-16, ISSN 0049-0172, https://doi.org/10.1016/j.semarthrit.2020.04.008. 18. Jiang J, Zhang T, Liu Y, Chang Q, Zhao Y, Guo C, Xia Y. Prevalence of Diabetes in Patients with Hyperuricemia and Gout: A Systematic Review and Meta-analysis. Curr Diab Rep. 2023 Jun;23(6):103-117. doi: 10.1007/s11892-023- 01506-2. Epub 2023 Apr 26. PMID: 37099085. 19. Jones NT, Abadie R, Keller CL, Jones K, Ledet Iii LF, Fox JE, Klapper VG, Potharaju P, Siddaiah H, Kaye AM, Shekoohi S, Kaye AD, Varrassi G. Treatment and Toxicity Considerations in Tuberculosis: A Narrative Review. Cureus. 2024 Jun 19;16(6):e62698. doi: 10.7759/cureus.62698. PMID: 39036175; PMCID: PMC11259524. 20. Khandwala P, Desai D, Sen M. Obstructive Sleep Apnea: A Contributing Factor in Gout. Cureus. 2024 Jan 11;16(1):e52115. doi: 10.7759/cureus.52115. PMID: 38344618; PMCID: PMC10858747. 21. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015 Nov;11(11):649-62. doi: 10.1038/nrrheum.2015.91. Epub 2015 Jul 7. PMID: 26150127. 22. Sosa F, Shaban M, Lopez J, Duarte GJ, Jain S, Khizar A, Vittorio T, Mishra R, Rodriguez Guerra M. Impact of Hyperuricemia and Urate-Lowering Agents on Cardiovascular Diseases. Clin Med Insights Cardiol. 2024 Mar 24;18:11795468241239542. doi: 10.1177/11795468241239542. PMID: 38529322; PMCID: PMC10962038.